Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany

Vaccine

Volumn 32, Issue 43, 2014, Pages 5564-5569

  Rieck, Thorsten ^a,b   Feig, Marcel ^a   Deleré, Yvonne ^a   Wichmann, Ole ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Administrative data; Adolescence; Germany; Health services research; Papillomavirus vaccine; Vaccination coverage

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADOLESCENT HEALTH; ARTICLE; CHILD; COHORT ANALYSIS; FEMALE; FOLLOW UP; GERMANY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; PHYSICIAN; PREVENTIVE HEALTH SERVICE; VACCINATION; VERRUCA VULGARIS; WART VIRUS; CHILD HEALTH CARE; PAPILLOMAVIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; CHILD; FEMALE; GERMANY; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVENTIVE HEALTH SERVICES; VACCINATION;

EID: 84908539265     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.105     Document Type: Article

References (36)

1. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632.
2. European Centre for Disease Prevention and Control. Vaccine schedule. Available from: [cited 09.12.13]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
3. European Centre for Disease Prevention and Control Introduction of HPV vaccines in European countries - an update 2012, ECDC, Stockholm.
4. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De Borba P., Zahaf T., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28(38):6247-6255.
5. GlaxoSmithKline Vaccine HPVSG, Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374(9706):1975-1985.
6. Konno R., Tamura S., Dobbelaere K., Yoshikawa H. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20-25 years: final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer 2010, 20(5):847-855.
7. Lu B., Kumar A., Castellsague X., Giuliano A.R. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis 2011, 11:13.
8. Roteli-Martins C.M., Naud P., De Borba P., Teixeira J.C., De Carvalho N.S., Zahaf T., et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012, 8(3):390-397.
9. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction--the first five years. Vaccine 2012, 30(Suppl. 5):F139-F148.
10. Robert Koch Institute Vaccination schedule 2013, Available from: http://www.rki.de/DE/Content/Infekt/Impfen/Materialien/Downloads-Impfkalender/Impfkalender_Englisch.pdf?__blob=publicationFile [cited 09.12.13].
11. Delere Y., Bohmer M.M., Walter D., Wichmann O. HPV vaccination coverage among women aged 18-20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey. Hum Vaccin Immunother 2013, 9(8).
12. Ministry of Environment-Health-Consumer Protection. Gesundheitsplattform - Tabelle - Impfschutz Schulabgänger: HPV. Available from: [cited 12.12.13]. http://www.gesundheitsplattform.brandenburg.de/sixcms/detail.php%3Fgsid=bb2.c.562425.de.
13. State Office of Health and Social Welfare - Mecklenburg-Western Pomerania. Impfreport 2010-2011 Mecklenburg-Vorpommern. Available from: . http://service.mvnet.de/_php/download.php%3Fdatei_id=52605.
14. Federal Committee of Medical Practitioners and Health Insurance. Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über die Früherkennung von Krankheiten bei Kindern bis zur Vollendung des 6. Lebensjahres ("Kinder-Richtlinien") in der Fassung vom 26. April 1976, zuletzt geändert am 16. Dezember 2010. Bundesanzeiger 2011, 40:1013.
15. Federal Joint Commitee Richtlinien des Bundesausschusses der Ärzte und Krankenkassen zur Jugendgesundheitsuntersuchung vom 26. Juni 1998 (veröffentlicht im Bundesanzeiger Nr. 159 vom 27. August 1998). Bundesanzeiger 2008, 40.
16. Kalies H., Redel R., Varga R., Tauscher M., von Kries R. Vaccination coverage in children can be estimated from health insurance data. BMC Public Health 2008, 8:82.
17. Reuss A.M., Feig M., Kappelmayer L., Siedler A., Eckmanns T., Poggensee G. Varicella vaccination coverage of children under two years of age in Germany. BMC Public Health 2010, 10:502.
18. Reuss A.M., Walter D., Feig M., Kappelmayer L., Buchholz U., Eckmanns T., et al. Influenza vaccination coverage in the 2004/05, 2005/06, and 2006/07 seasons: a secondary data analysis based on billing data of the German associations of statutory health insurance physicians. Dtsch Arztebl Int 2010, 107(48):845-850.
19. Rieck T., Feig M., Eckmanns T., Benzler J., Siedler A., Wichmann O. Vaccination coverage among children in Germany estimated by analysis of health insurance claims data. Hum Vaccin Immunother 2013, 10(2).
20. Robert Koch Institute Erinnern nützt - Pilotaktion zur Steigerung der Teilnahme an der Vorsorgeuntersuchung J1 in Mecklenburg-Vorpommern. Epid Bull 2012, 37:365-367.
21. German federal statistical office. Tabelle 12411-0012: Bevölkerung: Bundesländer, Stichtag, Geschlecht, Altersjahre (Fortschreibung) [Internet]. Available from: [cited 13.03.14]. https://www-genesis.destatis.de/genesis/online%3Fsequenz=tabelleAufbau%26selectionname=12411-0012%26sprache=de.
22. State Office for Information and Technology Northrhine-Westphalia. Landesdatenbank NRW, Tabelle 12411-10ir: Bevölkerungsstand nach Altersjahren (90) und Geschlecht - Gemeinden - Stichtag. Available from: [cited 13.03.14]. https://www.landesdatenbank.nrw.de/ldbnrw/online/data%3bjsessionid=8EA2DDDCBF2C4DCE3A73A477D936599A%3Foperation=abruftabelleAbrufen%26selectionname=12411-10ir%26levelindex=1%26levelid=1386864098298%26index=13.
23. KM 6-Statistik (gesetzliche Krankenversicherung: Versicherte) [Internet]. Available from: . http://www.gbe-bund.de/gbe10/ergebnisse.prc_tab?fid=9156%26suchstring=%26query_id=%26sprache=D%26fund_typ=DQ%26methode=%26vt=%26verwandte=1%26page_ret=0%26seite=1%26p_lfd_nr=13%26p_news=%26p_sprachkz=D%26p_uid=gast%26p_aid=94167780%26hlp_nr=2%26p_janein=J.
24. Federal Centre for Health Education Youth sexuality 2010. Repeat survey of 14 to 17-year-olds and their parents - current focus: migration. Cologne, Germany 2010, Available from: http://www.bzga.de/pdf.php?id=953c2042a48e51659f5f18a0756f9569.
25. Delere Y., Remschmidt C., Leuschner J., Schuster M., Fesenfeld M., Schneider A., et al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis 2014, 14(1):87.
26. Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Gonzalez P., Kreimer A.R., et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011, 1(5):408-419.
27. Hock S., Berchner Y., Blankenstein O., Buschbaum T., Ellsasser G., Heuermann M.W., et al. Status quo of children's preventative medicine programmes - results of the first German nationwide workshop 2011 in Frankfurt am Main. Gesundheitswesen 2013, 75(3):143-148.
28. Thaiss H., Klein R., Schumann E.C., Ellsasser G., Breitkopf H., Reinecke H., et al. Child health check-ups as an instrument in child welfare. First results of compulsory check-up systems in German federal states. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010, 53(10):1029-1047.
29. Bohmer M.M., Hellenbrand W., Matysiak-Klose D., Heininger U., Muters S., Wichmann O. Pertussis vaccination coverage among adults in Germany. Dtsch Med Wochenschr 2013, 138(28-29):1451-1457.
30. Bohmer M.M., Walter D., Krause G., Muters S., Gosswald A., Wichmann O. Determinants of tetanus and seasonal influenza vaccine uptake in adults living in Germany. Hum Vaccin 2011, 7(12):1317-1325.
31. Schaade L., Widders U., Stange G., Höhl N. Impfempfehlungen der Ständigen Impfkommission beim Robert Koch-Institut. Rechtliche Grundlagen und rechtliche Bedeutung. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2009, 52(11):1006-1010.
32. Walter D., Schmich P., Wetzstein M., Deleré D., Wichmann O. C.R. Knowledge, attitude, and uptake related to human papillomavirus vaccination among young women in Germany recruited via a social media site. Hum Vaccin Immunother 2014, 10(9).
33. Robert Koch Institute Daten und Fakten: Ergebnisse der Studie 'Gesundheit in Deutschland aktuell 2010' 2012, Beiträge zur Gesundheitsberichterstattung des Bundes RKI, Berlin.
34. Robert Koch Institute Impfquoten bei der Schuleingangsuntersuchung in Deutschland 2011. Epid Bull 2013, 129-133. [Nr. 16 vom 22. April 2013].
35. Huber J., Lampert T., Mielck A. Inequalities in health risks, morbidity and health care of children by health insurance of their parents (statutory vs. private health insurance): results of the German KiGGS study. Gesundheitswesen 2012, 74(10):627-638.
36. Richtlinie des Gemeinsamen Bundesausschusses über Schutzimpfungen nach § 20 d, Abs. 1 SGB V (Schutzimpfungs-Richtlinie/SI-RL) in der Fassung vom 18. Oktober 2007, zuletzt geändert am 5. Dezember 2013 [Internet]. 2013. Available from: . http://www.g-ba.de/informationen/richtlinien/60/.